{"name":"Belarusian Research Center for Pediatric Oncology, Hematology and Immunology","slug":"belarusian-research-center-for-pediatric-oncology-hematology-and-immunology","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NK cell infusions","genericName":"NK cell infusions","slug":"nk-cell-infusions","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"NK cell infusions","genericName":"NK cell infusions","slug":"nk-cell-infusions","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9sYUw5S1FOSm5halU2bWNBcXpmZVJUN2EwbmstLS02OFFsYzNCTDYyb2RIZWRrSWxVbEtEYkdXdlFKVmt2X0ZqUUhFemdUZTFGVUVpQUc0dWVhcU1fMW9v?oc=5","date":"2025-11-05","type":"pipeline","source":"Nature","summary":"The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Quality Management Group – Poster Session (P943-P964) | Bone Marrow Transplantation - Nature","headline":"The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Quality Management Group – Poster ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5RazNITGlMMVpXand5Q2hBMDhfVW5DQmZ6SW95bHNrZFdGOFZyRzhGdlJ6X1JFRTlEZTR0UVdwVmJ6R3ZCNGR1OWZybU1UU0cyajliWTVBbzJfWENkQkE?oc=5","date":"2020-03-17","type":"trial","source":"Nature","summary":"Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study - Nature","headline":"Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFBOeGlXSVNlMy1BR2hIcF9EVi0tN19nbEdxckVQYXpzWHhNT3pNQTRsMTZnTmtzYldxdGtKZWRpVV9jSGtLVENKVlphc0t0R2xBazFtMQ?oc=5","date":"2017-07-13","type":"pipeline","source":"Nature","summary":"The MLL recombinome of acute leukemias in 2017 - Nature","headline":"The MLL recombinome of acute leukemias in 2017","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFBPSFp5NlB6OUIwRkxCNHNpVmNyakZqVkRaZUpGNGQ5WDdPcHlMSWdNQVZPZFpkTUQxcjRsZWNaeEJUZnlGNlVMWU1QSG1RY0FiN3I2OA?oc=5","date":"2013-04-30","type":"pipeline","source":"Nature","summary":"The MLL recombinome of acute leukemias in 2013 - Nature","headline":"The MLL recombinome of acute leukemias in 2013","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}